Cargando…

Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients

The present study analyzed the predictive value of combined analysis of collapsin response mediator protein 4 (CRMP4) methylation levels and the Cancer of the Prostate Risk Assessment (CAPRA-S) Postsurgical score of patients who required adjuvant hormone therapy (AHT) after radical prostatectomy (RP...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qun-Xiong, Xiao, Chu-Tian, Chen, Zheng, Lu, Min-Hua, Pang, Jun, Di, Jin-Ming, Luo, Zi-Huan, Gao, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753555/
https://www.ncbi.nlm.nih.gov/pubmed/28382925
http://dx.doi.org/10.4103/aja.aja_3_17
_version_ 1783290298050281472
author Huang, Qun-Xiong
Xiao, Chu-Tian
Chen, Zheng
Lu, Min-Hua
Pang, Jun
Di, Jin-Ming
Luo, Zi-Huan
Gao, Xin
author_facet Huang, Qun-Xiong
Xiao, Chu-Tian
Chen, Zheng
Lu, Min-Hua
Pang, Jun
Di, Jin-Ming
Luo, Zi-Huan
Gao, Xin
author_sort Huang, Qun-Xiong
collection PubMed
description The present study analyzed the predictive value of combined analysis of collapsin response mediator protein 4 (CRMP4) methylation levels and the Cancer of the Prostate Risk Assessment (CAPRA-S) Postsurgical score of patients who required adjuvant hormone therapy (AHT) after radical prostatectomy (RP). We retrospectively analyzed 305 patients with prostate cancer (PCa) who received RP and subsequent androgen deprivation therapy (ADT). Two hundred and thirty patients with clinically high-risk PCa underwent immediate ADT, and 75 patients with intermediate risk PCa underwent deferred ADT. CRMP4 methylation levels in biopsies were determined, and CAPRA-S scores were calculated. In the deferred ADT group, the values of the hazard ratios for tumor progression and cancer-specific mortality (CSM) in patients with ≥15% CRMP4 methylation were 6.81 (95% CI: 2.34–19.80) and 12.83 (95% CI: 2.16–26.10), respectively. Receiver-operating characteristic curve analysis indicated that CRMP4 methylation levels ≥15% served as a significant prognostic marker of tumor progression and CSM. In the immediate ADT group, CAPRA-S scores ≥6 and CRMP4 methylation levels ≥15% were independent predictors of these outcomes (uni- and multi-variable Cox regression analyses). The differences in the 5-year progression-free survival between each combination were statistically significant. Combining CAPRA-S score and CRMP4 methylation levels improved the area under the curve compared with the CRMP4 or CAPRA-S model. Therefore, CRMP4 methylation levels ≥15% were significantly associated with a poor prognosis and their combination with CAPRA-S score accurately predicted tumor progression and metastasis for patients requiring AHT after RP.
format Online
Article
Text
id pubmed-5753555
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-57535552018-01-05 Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients Huang, Qun-Xiong Xiao, Chu-Tian Chen, Zheng Lu, Min-Hua Pang, Jun Di, Jin-Ming Luo, Zi-Huan Gao, Xin Asian J Androl Original Article The present study analyzed the predictive value of combined analysis of collapsin response mediator protein 4 (CRMP4) methylation levels and the Cancer of the Prostate Risk Assessment (CAPRA-S) Postsurgical score of patients who required adjuvant hormone therapy (AHT) after radical prostatectomy (RP). We retrospectively analyzed 305 patients with prostate cancer (PCa) who received RP and subsequent androgen deprivation therapy (ADT). Two hundred and thirty patients with clinically high-risk PCa underwent immediate ADT, and 75 patients with intermediate risk PCa underwent deferred ADT. CRMP4 methylation levels in biopsies were determined, and CAPRA-S scores were calculated. In the deferred ADT group, the values of the hazard ratios for tumor progression and cancer-specific mortality (CSM) in patients with ≥15% CRMP4 methylation were 6.81 (95% CI: 2.34–19.80) and 12.83 (95% CI: 2.16–26.10), respectively. Receiver-operating characteristic curve analysis indicated that CRMP4 methylation levels ≥15% served as a significant prognostic marker of tumor progression and CSM. In the immediate ADT group, CAPRA-S scores ≥6 and CRMP4 methylation levels ≥15% were independent predictors of these outcomes (uni- and multi-variable Cox regression analyses). The differences in the 5-year progression-free survival between each combination were statistically significant. Combining CAPRA-S score and CRMP4 methylation levels improved the area under the curve compared with the CRMP4 or CAPRA-S model. Therefore, CRMP4 methylation levels ≥15% were significantly associated with a poor prognosis and their combination with CAPRA-S score accurately predicted tumor progression and metastasis for patients requiring AHT after RP. Medknow Publications & Media Pvt Ltd 2018 2017-04-04 /pmc/articles/PMC5753555/ /pubmed/28382925 http://dx.doi.org/10.4103/aja.aja_3_17 Text en Copyright: © The Author(s)(2017) http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Huang, Qun-Xiong
Xiao, Chu-Tian
Chen, Zheng
Lu, Min-Hua
Pang, Jun
Di, Jin-Ming
Luo, Zi-Huan
Gao, Xin
Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients
title Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients
title_full Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients
title_fullStr Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients
title_full_unstemmed Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients
title_short Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients
title_sort combined analysis of crmp4 methylation levels and capra-s score predicts metastasis and outcomes in prostate cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753555/
https://www.ncbi.nlm.nih.gov/pubmed/28382925
http://dx.doi.org/10.4103/aja.aja_3_17
work_keys_str_mv AT huangqunxiong combinedanalysisofcrmp4methylationlevelsandcaprasscorepredictsmetastasisandoutcomesinprostatecancerpatients
AT xiaochutian combinedanalysisofcrmp4methylationlevelsandcaprasscorepredictsmetastasisandoutcomesinprostatecancerpatients
AT chenzheng combinedanalysisofcrmp4methylationlevelsandcaprasscorepredictsmetastasisandoutcomesinprostatecancerpatients
AT luminhua combinedanalysisofcrmp4methylationlevelsandcaprasscorepredictsmetastasisandoutcomesinprostatecancerpatients
AT pangjun combinedanalysisofcrmp4methylationlevelsandcaprasscorepredictsmetastasisandoutcomesinprostatecancerpatients
AT dijinming combinedanalysisofcrmp4methylationlevelsandcaprasscorepredictsmetastasisandoutcomesinprostatecancerpatients
AT luozihuan combinedanalysisofcrmp4methylationlevelsandcaprasscorepredictsmetastasisandoutcomesinprostatecancerpatients
AT gaoxin combinedanalysisofcrmp4methylationlevelsandcaprasscorepredictsmetastasisandoutcomesinprostatecancerpatients